Website Overview: imfinzi.comopen_in_new

General information

Last Updated: 2024-04-09 (yyyy-mm-dd).

Title: Immunotherapy for BTC uHCC NSCLC ES SCLC IMFINZI durvalumab

Description: IMFINZI durvalumab is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma bile duct cancer gallbladder cancer unresectable Stage 3 NSCLC Stage 4 NSCLC and extensive stage SCLC

Language: English

Contact information

Telephone

• 1800FDA1088

Services and technology that the website used

Vendor

• Email Vendor: cscdns.net

Related Websites

• azpicentral.com
• astrazeneca.com
• astrazeneca-us.com
• azprivacynotice.com